LAUSR

Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside‐modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae. Because plazomicin is predominantly eliminated via renal pathways, an in vitro study was conducted to determine whether plazomicin inhibits the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion (MATE1 and MATE2‐K) transporters, using metformin as a probe substrate. Plazomicin inhibited OCT2, MATE1, and MATE2‐K transporters with half‐maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively. To determine whether this in vitro inhibition translates in vivo, an open‐label, randomized, 2‐period, 2‐treatment crossover study (NCT03270553) was carried out in healthy subjects (N = 16), who received a single oral dose of metformin 850 mg alone and in combination with a single intravenous infusion of plazomicin 15 mg/kg. Geometric least‐squares mean ratios of the test treatment (combination) vs the reference treatment (metformin alone) and 90% confidence intervals were within the equivalence interval of 80% to 125% (peak plasma concentration, 104.5 [95.1–114.9]; area under the plasma concentration–time curve from time zero to time of last quantifiable concentration, 103.7 [93.5–115.0]; area under the plasma concentration–time curve from time zero to infinity, 104.0 [94.2–114.8]). The results demonstrate that there is no clinically significant drug‐drug interaction resulting from coadministration of single doses of intravenous plazomicin 15 mg/kg and oral metformin 850 mg in healthy subjects. Coadministration of plazomicin and metformin was well tolerated in healthy subjects.